| Pembrolizumab versus ipilimumab in advanced melanoma C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... New England Journal of Medicine 372 (26), 2521-2532, 2015 | 6180 | 2015 |
| Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ... New England Journal of Medicine 369 (2), 134-144, 2013 | 4193 | 2013 |
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations KT Flaherty, JR Infante, A Daud, R Gonzalez, RF Kefford, J Sosman, ... New England Journal of Medicine 367 (18), 1694-1703, 2012 | 3128 | 2012 |
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial C Robert, A Ribas, JD Wolchok, FS Hodi, O Hamid, R Kefford, JS Weber, ... The Lancet 384 (9948), 1109-1117, 2014 | 2105 | 2014 |
| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ... The lancet oncology 16 (8), 908-918, 2015 | 1766 | 2015 |
| Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) J Schachter, A Ribas, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... The Lancet 390 (10105), 1853-1862, 2017 | 1299 | 2017 |
| PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma PT Nghiem, S Bhatia, EJ Lipson, RR Kudchadkar, NJ Miller, L Annamalai, ... New England Journal of Medicine 374 (26), 2542-2552, 2016 | 1298 | 2016 |
| Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity ML Broz, M Binnewies, B Boldajipour, AE Nelson, JL Pollack, DJ Erle, ... Cancer cell 26 (5), 638-652, 2014 | 1203 | 2014 |
| Association of pembrolizumab with tumor response and survival among patients with advanced melanoma A Ribas, O Hamid, A Daud, FS Hodi, JD Wolchok, R Kefford, AM Joshua, ... Jama 315 (15), 1600-1609, 2016 | 1118 | 2016 |
| Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study C Robert, A Ribas, J Schachter, A Arance, JJ Grob, L Mortier, A Daud, ... The Lancet Oncology 20 (9), 1239-1251, 2019 | 1048 | 2019 |
| Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma AI Daud, RC DeConti, S Andrews, P Urbas, AI Riker, VK Sondak, ... Journal of clinical oncology 26 (36), 5896-5903, 2008 | 853 | 2008 |
| A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments KC Barry, J Hsu, ML Broz, FJ Cueto, M Binnewies, AJ Combes, ... Nature medicine 24 (8), 1178-1191, 2018 | 837 | 2018 |
| Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ... Annals of Oncology 30 (4), 582-588, 2019 | 820 | 2019 |
| Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 CS Garris, SP Arlauckas, RH Kohler, MP Trefny, S Garren, C Piot, ... Immunity 49 (6), 1148-1161. e7, 2018 | 802 | 2018 |
| Phase I study of pembrolizumab (MK-3475; anti–PD-1 monoclonal antibody) in patients with advanced solid tumors A Patnaik, SP Kang, D Rasco, KP Papadopoulos, J Elassaiss-Schaap, ... Clinical cancer research 21 (19), 4286-4293, 2015 | 787 | 2015 |
| Evaluation of immune-related response criteria and RECIST v1. 1 in patients with advanced melanoma treated with pembrolizumab FS Hodi, WJ Hwu, R Kefford, JS Weber, A Daud, O Hamid, A Patnaik, ... Journal of Clinical Oncology 34 (13), 1510-1517, 2016 | 750 | 2016 |
| Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable … A Hauschild, SS Agarwala, U Trefzer, D Hogg, C Robert, P Hersey, ... Journal of Clinical Oncology 27 (17), 2823-2830, 2009 | 693 | 2009 |
| Programmed death-ligand 1 expression and response to the anti–programmed death 1 antibody Pembrolizumab in melanoma AI Daud, JD Wolchok, C Robert, WJ Hwu, JS Weber, A Ribas, FS Hodi, ... Journal of Clinical Oncology 34 (34), 4102-4109, 2016 | 631 | 2016 |
| A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies C Aghajanian, S Soignet, DS Dizon, CS Pien, J Adams, PJ Elliott, ... Clinical cancer research 8 (8), 2505-2511, 2002 | 615 | 2002 |
| The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis AI Riker, SA Enkemann, O Fodstad, S Liu, S Ren, C Morris, Y Xi, P Howell, ... BMC medical genomics 1, 1-16, 2008 | 584 | 2008 |
Antoni RibasUCLA在 mednet.ucla.edu 的电子邮件经过验证
